Compare RingCentral Inc. Class A Common Stock (RNG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RingCentral Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? RingCentral Inc. Class A Common Stock trades at $75.1 (market cap $6.53B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: RingCentral Inc. Class A Common Stock is the larger of the two by market cap, and RingCentral Inc. Class A Common Stock pays a 0.35% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold RingCentral Inc. Class A Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| RNG | TNGX | |
|---|---|---|
Market Cap | $6.53B | $3.75B |
Volume | 1,430,504 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $79.82 | $32.90 |
52-Week Low | $24.82 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.58B | $2.77B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RingCentral (RNG) trades at $78.69, up 0.67% on the day and near its 52-week high, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend. Fundamentally, the company shows revenue growth to $2.52 billion in 2025, with net income of $43.39 million and improving margins. Recent earnings beats and strategic AI partnerships, like the one with Allnet.Italia announced October 13, 2026, underscore growth potential. Analyst sentiment is overwhelmingly positive with 28 buy ratings and a consensus price target of $61.00, though the current price exceeds this target.
The outlook for RNG is favorable driven by AI integration and earnings momentum, but risks include high valuation with a P/E of 62.54 and potential volatility ahead of Q3 2026 results on October 22, 2026. Investor focus remains on execution and margin expansion amid competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RingCentral Inc. Class A Common Stock
RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.
Read more on RNG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
